ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Therapeutic targeting of adhesion GPCRs: a status update and future potential.Expert opinion on drug discovery · 2026Review
- Adhesion G protein-coupled receptors.Pharmacological reviews · 2026Review
- Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy.Clinical and experimental medicine · 2024Review
- New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.Frontiers in immunology · 2024Review
- Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.Journal of translational medicine · 2023Review
- esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation.Molecular therapy oncolytics · 2023Article
- Role of Adhesion G Protein-Coupled Receptors in Immune Dysfunction and Disorder.International journal of molecular sciences · 2023Review
- Adhesion G protein-coupled receptors: structure, signaling, physiology, and pathophysiology.Physiological reviews · 2022Review
- NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.Brain tumor pathology · 2022Review
- Tumor-Associated Macrophages/Microglia in Glioblastoma Oncolytic Virotherapy: A Double-Edged Sword.International journal of molecular sciences · 2022Review
- Review
- An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma.Nature communications · 2021Article
- Therapeutic Application of Brain-Specific Angiogenesis Inhibitor 1 for Cancer Therapy.Cancers · 2021Review
- The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment.Oncolytic virotherapy · 2021Review
- Article
- Lifting the innate immune barriers to antitumor immunity.Journal for immunotherapy of cancer · 2020Review
- Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF- and M-CSF-Differentiated Bone Marrow-Derived Cells.Journal of proteome research · 2020Article
- Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy.Current clinical microbiology reports · 2019Article
- Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.Molecular therapy oncolytics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 5 institutions in 1 country.
Chelsea BolyardDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
W Hans MeisenDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Yeshavanth Banasavadi-SiddegowdaDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Jayson HardcastleDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Ji Young YooDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Eric S WohlebDepartment of Neuroscience, The Ohio State University Wexner Medical Center, Columbus, Ohio.
Jeffrey WojtonDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Jun-Ge YuThe James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Samuel DubinDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Maninder KhoslaThe James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Bo XuThe James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Jonathan SmithDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Christopher Alvarez-BreckenridgeDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Pete Pow-AnpongkulDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio.
Flavia PichiorriDepartment of Hematology, City of Hope Cancer Center, Duarte, California.
Jianying ZhangThe James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Matthew OldThe James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Dan ZhuDepartments of Neurosurgery and Hematology and Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, Georgia.
Erwin G Van MeirDepartments of Neurosurgery and Hematology and Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, Georgia.
Jonathan P GodboutThe James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Michael A CaligiuriThe James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Jianhua YuThe James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Balveen KaurDepartment of Neurological Surgery, The Ohio State University College of Medicine, Columbus, Ohio. Balveen.Kaur@osumc.edu.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe Ohio State University · USEmory University · USCity of Hope · USThe Ohio State University Wexner Medical Center · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTransgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3MWinship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5MThe Tumor Microenvironmental Barrier to Effective Viral OncolysisP01CA163205 · NCI · OHIO STATE UNIVERSITY · PI MICHAEL A CALIGIURI · 2013 to 2026
$26.0MONOCOLOGY TRAINING GRANTT32CA009338 · NCI · OHIO STATE UNIVERSITY · PI BYRD, JOHN C., POLLOCK, RAPHAEL E. · 1985 to 2018
$8.3MOhio State Neuroscience Centr CoreP30NS045758 · NINDS · OHIO STATE UNIVERSITY · PI OBRIETAN, KARL H · 2004 to 2015
$7.7MEnhancing Viral Oncolysis with Vasculostatin Gene DeliveryR01CA150153 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KAUR, BALVEEN · 2011 to 2020
$4.0MTHERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMASR01CA086335 · NCI · EMORY UNIVERSITY · PI VAN MEIR, ERWIN G. · 2000 to 2011
$3.9MOV Therapy Induced Changes in Tumor Secretome and Their Impact on TherapyR01NS064607 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KAUR, BALVEEN · 2008 to 2018
$3.2MTargeting Mechanisms of Medulloblastoma FormationR01NS096236 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI VAN MEIR, ERWIN G. · 2016 to 2020
$1.9MDefining mechanisms of extracellular communication for cancer therapyR01CA163722 · NCI · EMORY UNIVERSITY · PI VAN MEIR, ERWIN G. · 2013 to 2017
$1.7MNCI NIH HHS P01 CA163205NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA033572NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA086335NCI NIH HHS R01 CA150153NCI NIH HHS R01 CA163722NCI NIH HHS T32 CA009338NINDS NIH HHS P30 NS045758NINDS NIH HHS R01 NS064607NINDS NIH HHS R01 NS096236
Abstract
PubMed holds no abstract for this paper.
Indexed as
Angiogenic ProteinsAnimalsBrainCell Line, TumorGliomaHumansInflammationMacrophagesMiceMicrogliaOncolytic VirotherapyOncolytic VirusesReceptors, G-Protein-CoupledSimplexvirusXenograft Model Antitumor AssaysADGRB1 protein, humanAngiogenic ProteinsReceptors, G-Protein-Coupled
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.